For patients who are unable to reap cholesterol-lowering benefits from the drugs known as statins due to intolerable side effects, technology may soon offer an alternative and effective treatment. While statins, including the most commonly used atorvastatin (Lipitor), simvastatin (Zocor) and rosuvastatin (Crestor) are the first line of treatment for reducing levels of the artery-clogging fatty deposits that increase bad cholesterol (LDL) levels, a new class of drugs may provide an unmet need in cholesterol-lowering alternatives, according to Michael Rocco, MD, Medical Director of Cardiac Rehabilitation and Stress Testing and staff cardiologist at Cleveland Clinic.
To continue reading this article or issue you must be a paid subscriber.
Sign in
